Novonesis Boosts 2026 Outlook on 8% H1 Sales Growth, Launches €1B Share Buyback
Event summary
- Novonesis reported 8% organic sales growth in H1 2026, with Q2 growth at 9%.
- Adjusted EBITDA margin improved to 37.7%, up 30bps year-over-year.
- Company raised full-year organic sales growth outlook to 7-8% from 5-7%.
- Inaugural €1B share buyback program approved, to run through 2029.
- Agreement signed to acquire remaining 77% of MicroBioGen.
The big picture
Novonesis's strong H1 performance reflects growing demand for biosolutions across developed and emerging markets. The share buyback signals confidence in maintaining profitability while returning capital to shareholders. The MicroBioGen acquisition suggests strategic focus on expanding core capabilities in biosolutions.
What we're watching
- Execution Risk
- Whether Novonesis can sustain elevated growth rates amid market exits.
- Capital Allocation
- The pace at which the €1B share buyback program progresses.
- Integration Challenge
- How MicroBioGen acquisition impacts Novonesis's biosolutions portfolio.
Related topics